Special items: Ovarian Cancer and Us blog best viewed in Firefox

Friday, January 22, 2010

Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study

"Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.